MCID: AGG011
MIFTS: 22

Aggressive B-Cell Non-Hodgkin Lymphoma

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Aggressive B-Cell Non-Hodgkin Lymphoma

MalaCards integrated aliases for Aggressive B-Cell Non-Hodgkin Lymphoma:

Name: Aggressive B-Cell Non-Hodgkin Lymphoma 58
Aggressive B-Cell Nhl 58

Characteristics:

Orphanet epidemiological data:

58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Orphanet 58 ORPHA300846

Summaries for Aggressive B-Cell Non-Hodgkin Lymphoma

MalaCards based summary : Aggressive B-Cell Non-Hodgkin Lymphoma, also known as aggressive b-cell nhl, is related to lymphoma, hodgkin, classic and lymphoma, non-hodgkin, familial. An important gene associated with Aggressive B-Cell Non-Hodgkin Lymphoma is HSPH1 (Heat Shock Protein Family H (Hsp110) Member 1). The drugs Gemcitabine and Pixantrone have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone marrow.

Related Diseases for Aggressive B-Cell Non-Hodgkin Lymphoma

Diseases related to Aggressive B-Cell Non-Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 18)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 11.0
2 lymphoma, non-hodgkin, familial 11.0
3 b-cell non-hodgkin lymphoma 11.0
4 lymphoma 10.8
5 b-cell lymphoma 10.8
6 diffuse large b-cell lymphoma 10.7
7 neutropenia 10.7
8 follicular lymphoma 10.5
9 burkitt lymphoma 10.3
10 mantle cell lymphoma 10.3
11 hypophosphatemia 10.2
12 relapsed/refractory diffuse large b-cell lymphoma 10.2
13 thrombocytopenia 10.2
14 peripheral nervous system disease 10.2
15 severe combined immunodeficiency 10.2
16 neuropathy 10.2
17 pulmonary embolism 10.2
18 acute graft versus host disease 10.2

Graphical network of the top 20 diseases related to Aggressive B-Cell Non-Hodgkin Lymphoma:



Diseases related to Aggressive B-Cell Non-Hodgkin Lymphoma

Symptoms & Phenotypes for Aggressive B-Cell Non-Hodgkin Lymphoma

Drugs & Therapeutics for Aggressive B-Cell Non-Hodgkin Lymphoma

Drugs for Aggressive B-Cell Non-Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3 95058-81-4 60750
2
Pixantrone Approved, Investigational Phase 3 144510-96-3
3
Blinatumomab Approved, Investigational Phase 2, Phase 3 853426-35-4
4
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Lenalidomide Approved Phase 3 191732-72-6 216326
7
rituximab Approved Phase 3 174722-31-7 10201696
8
Etoposide Approved Phase 3 33419-42-0 36462
9
Lenograstim Approved, Investigational Phase 3 135968-09-1
10
Mesna Approved, Investigational Phase 3 3375-50-6 598
11
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
12
Ifosfamide Approved Phase 3 3778-73-2 3690
13 Bendamustine Hydrochloride Phase 3
14 Antineoplastic Agents, Immunological Phase 3
15 Antirheumatic Agents Phase 3
16 Immunologic Factors Phase 3
17 Etoposide phosphate Phase 3
18 Alkylating Agents Phase 3
19
Isophosphamide mustard Phase 3 100427
20
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
21
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
22
Busulfan Approved, Investigational Phase 2 55-98-1 2478
23
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
24
Cytarabine Approved, Investigational Phase 2 147-94-4 6253
25
Bevacizumab Approved, Investigational Phase 2 216974-75-3
26
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
27
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
28
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
29
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
30
leucovorin Approved Phase 2 58-05-9 6006
31
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
32
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
33
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
34
nivolumab Approved Phase 2 946414-94-4
35
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
36
Cortisone Experimental Phase 2 53-06-5 222786
37 Calcineurin Inhibitors Phase 2
38 Antifungal Agents Phase 2
39 Cyclosporins Phase 2
40 Anti-Infective Agents Phase 2
41 Antiviral Agents Phase 2
42 Antimetabolites Phase 2
43 Adjuvants, Immunologic Phase 2
44 Vitamin B9 Phase 2
45 Folic Acid Antagonists Phase 2
46 Gastrointestinal Agents Phase 2
47 Vitamin B Complex Phase 2
48 Antiemetics Phase 2
49 Folate Phase 2
50 BB 1101 Phase 2

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 A Randomized, Phase IIIB, Open-label, Two-arm, Multicenter, comparatiVe Study on Efficacy and Safety of Lipegfilgrastim (Lonquex, TEVA) in Comparison to Pegfilgrastim (Neulasta®, Amgen) in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia - AVOID Neutropenia Completed NCT02044276 Phase 3 lipegfilgrastim;pegfilgrastim
2 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
3 A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma Completed NCT02910063 Phase 2, Phase 3 Blinatumomab
4 Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA) Recruiting NCT03570892 Phase 3 Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy;Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
5 A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM). Recruiting NCT03575351 Phase 3 Standard of Care
6 A Randomized Phase III Trial of ICE Chemotherapy With or Without Rituximab for the Treatment of Relapsed or Refractory CD20 Expressing Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients Not Suitable for High Dose Therapy and PBSCT Terminated NCT00006708 Phase 3 carboplatin;etoposide;ifosfamide
7 Allogeneic Transplantation After a Conditioning With Thiotepa, Busulfan and Fludarabin for the Treatment of Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas: a Phase II Multi-Center Trial Unknown status NCT01786018 Phase 2 Thiotepa;Busulfan;Fludarabin;Immunosuppression;Cyclosporine;Methotrexate;ATG
8 Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation. Unknown status NCT00385125 Phase 2 Bendamustine;Rituximab
9 A Phase II Study of Dose Augmented Rituximab and Ice for Patients With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell Non-Hodgkin's Lymphoma Undergoing Second-Line Therapy Prior to Stem Cell Transplantation Completed NCT00588094 Phase 2 Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
10 A Phase II Study of Avastin Plus Rituximab for Patients With Relapsed and Chemotherapy- or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Completed NCT00081861 Phase 2 Avastin;Rituximab
11 A Phase II Randomized Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger Completed NCT00290498 Phase 2 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Methotrexate;Cytarabine;Prednisone
12 A Phase II Study Of Rituximab-CHOP With Pegylated Liposomal Doxorubicin In Patients Older Than 60 Years Of Age With Untreated Aggressive B-Cell Non-Hodgkin's Lymphoma Completed NCT00101010 Phase 2 Cyclophosphamide;Pegylated liposomal doxorubicin hydrochloride;Prednisone;Vincristine Sulfate
13 A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Recruiting NCT03749018 Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate
14 A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006) Active, not recruiting NCT03483103 Phase 2
15 Phase II Trial of TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma Not yet recruiting NCT04161118 Phase 2 CTL019
16 A Multicenter Phase I Clinical Trial to Assess the Safety of Two Consecutive Days of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma Completed NCT00794638 Phase 1 SyB L-0501;Rituximab
17 A Pilot Study to Estimate the Safety and Tolerability of the Combination of Polatuzumab Vedotin With Dose Adjusted Rituximab, Etoposide, Cyclophosphamide, and Doxorubicin (DA-EPCH-PR) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas Recruiting NCT04231877 Phase 1 Polatuzumab Vedotin;Prednisone;Etoposide;Doxorubicin;Cyclophosphamide
18 A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma Active, not recruiting NCT01840566 Phase 1 Carmustine;Etoposide;Cytarabine;Melphalan
19 A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Terminated NCT02702141 Phase 1 SGN-CD19B
20 (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell NHL Terminated NCT01300793 Phase 1 Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide
21 DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas Active, not recruiting NCT02633111
22 A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant Terminated NCT00515138 Early Phase 1 Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib
23 Evaluation of the Prognostic Value of Early Interim PET/CT for Prediction of Progression Free Survival of Patients With Aggressive B Cells Non Hodgkin Lymphoma Withdrawn NCT00498667

Search NIH Clinical Center for Aggressive B-Cell Non-Hodgkin Lymphoma

Genetic Tests for Aggressive B-Cell Non-Hodgkin Lymphoma

Anatomical Context for Aggressive B-Cell Non-Hodgkin Lymphoma

MalaCards organs/tissues related to Aggressive B-Cell Non-Hodgkin Lymphoma:

40
B Cells, T Cells, Bone Marrow, Spleen, Appendix

Publications for Aggressive B-Cell Non-Hodgkin Lymphoma

Articles related to Aggressive B-Cell Non-Hodgkin Lymphoma:

(show top 50) (show all 164)
# Title Authors PMID Year
1
Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. 61
32944800 2021
2
Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. 61
33146052 2021
3
Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization. 61
33799222 2021
4
High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas. 61
33694088 2021
5
Chimeric Antigen Receptor T Cells for B-Cell Lymphoma. 61
33750069 2021
6
Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma. 61
32550718 2021
7
Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin's lymphoma patients. 61
33608570 2021
8
The treatment of Burkitt lymphoma in adults. 61
33171490 2021
9
C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas. 61
33232481 2020
10
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. 61
32667831 2020
11
Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. 61
32546071 2020
12
Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not? 61
32304874 2020
13
Aggressive B-Cell Lymphoma Involving the Appendix and Bilateral Ovaries in an 11-Year-Old Girl. 61
32304857 2020
14
An HIV Associated Plasmablastic Lymphoma With Spontaneous Tumor Lysis Syndrome. 61
32923226 2020
15
Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway. 61
33225311 2020
16
Endemic Burkitt lymphoma: a complication of asymptomatic malaria in sub-Saharan Africa based on published literature and primary data from Uganda, Tanzania, and Kenya. 61
32718346 2020
17
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. 61
32141616 2020
18
Novel agents for mantle cell lymphoma: molecular rational and clinical data. 61
32321318 2020
19
Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. 61
31997425 2020
20
Burkitt lymphoma presenting with fever of unknown origin and isolated hypoglossal nerve palsy. 61
31425376 2020
21
Antiproliferative and proapoptotic effects of Inula viscosa extract on Burkitt lymphoma cell line. 61
32013807 2020
22
Primary Dural Diffuse Large B-cell Lymphoma: A Comprehensive Review of Survival and Treatment Outcomes. 61
31902733 2020
23
Chimeric Antigen Receptors for the Tumour Microenvironment. 61
32588326 2020
24
MicroRNA-21 and microRNA-155 promote the progression of Burkitt's lymphoma by the PI3K/AKT signaling pathway. 61
32055277 2020
25
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. 61
31568564 2020
26
Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). 61
31879945 2020
27
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. 61
31446199 2019
28
Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. 61
31441943 2019
29
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. 61
31868632 2019
30
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. 61
31342797 2019
31
Burkitt lymphoma of the maxilla in a HIV positive male - Presentation and review of diagnostic laboratory tests. 61
33282691 2019
32
Pixantrone beyond monotherapy: a review. 61
31312929 2019
33
Intussusception in children: lessons learned from intestinal lymphoma as a rare lead-point. 61
31139892 2019
34
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. 61
31262783 2019
35
The acceleration of CAR-T therapy in non-Hodgkin lymphoma. 61
30427551 2019
36
Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M. 61
31069789 2019
37
Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop. 61
30696305 2019
38
Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. 61
30702000 2019
39
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. 61
30782611 2019
40
Bilateral mantle cell lymphoma of the ciliary body that responded to a combined local radiotherapy and chemotherapy regimen: a case report. 61
30987612 2019
41
Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. 61
31043832 2019
42
Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma. 61
30919158 2019
43
CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma. 61
30557517 2019
44
The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions. 61
30280924 2019
45
Management of adults with Burkitt lymphoma. 61
30843890 2018
46
Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. 61
30166257 2018
47
High-grade Burkitt Lymphoma Presenting as a Buttock Mass and Foot Drop. 61
30510878 2018
48
Low rate of spleen involvement in sporadic Burkitt lymphoma at staging on PET-CT. 61
29460043 2018
49
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. 61
28677896 2018
50
Impact of salvage treatment modalities in patients with positive FDG-PET/CT after R-CHOP chemotherapy for aggressive B-cell non-Hodgkin lymphoma. 61
29577608 2018

Variations for Aggressive B-Cell Non-Hodgkin Lymphoma

Expression for Aggressive B-Cell Non-Hodgkin Lymphoma

Search GEO for disease gene expression data for Aggressive B-Cell Non-Hodgkin Lymphoma.

Pathways for Aggressive B-Cell Non-Hodgkin Lymphoma

GO Terms for Aggressive B-Cell Non-Hodgkin Lymphoma

Sources for Aggressive B-Cell Non-Hodgkin Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....